Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9PJZT)

Drug Name

Ipamorelin Drug Info

Synonyms

Ipamorelin [INN]; SCHEMBL18428173; DTXSID80168955; CI-304; 2-Methylalanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide; 2-Methylalanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide.; (2S)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[(2-amino-2-methylpropanoyl)amino]-3-(4H-imidazol-4-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanamide; 2-methylalanyl-L-histidyl-3-naphthalen-2-yl-D-alanyl-D-phenylalanyl-L-lysinamide, 2-Methylalanyl-L-histidyl-3-(2-naph

Indication

Disease Entry	ICD 11	Status	REF
Postoperative ileus	DA91-DB30	Phase 1/2	[1]

Cross-matching ID

PubChem CID: 9831659
CAS Number: CAS 170851-70-4
TTD Drug ID: DM9PJZT

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Growth hormone secretagogue receptor 1 (GHSR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GHRP-2	DMKGH0R	Growth hormone deficiency	5A61.3	Approved	[3]
Ibutamoren	DMFJ8LT	Fibromyalgia	MG30.01	Approved	[4]
Macimorelin	DMQYJIR	Growth hormone deficiency	5A61.3	Approved	[5]
Anamorelin	DM6HXTS	Carbohydrate metabolism disorder	5C51.Z	Phase 3	[6]
TZP-101	DMOE582	Gastrointestinal disease	DE2Z	Phase 2b	[7]
GTP-200	DM03NQS	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
RQ-00000005	DMBHN4K	Frailty	MG2A	Phase 2	[9]
Tabimorelin	DMNL9HO	Growth hormone deficiency	5A61.3	Phase 2	[10]
Ibutamoren mesylate	DMN2CM0	Growth hormone deficiency	5A61.3	Phase 2	[11]
PF-05190457	DM7B2JC	Type-2 diabetes	5A11	Phase 1	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Growth hormone secretagogue receptor 1 (GHSR)	TTWDC17	GHSR_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26.
2	Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.J Pharmacol Exp Ther.2009 Jun;329(3):1110-6.
3	GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology. 2002 Feb;143(2):558-68.
4	Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7001-5.
5	National Cancer Institute Drug Dictionary (drug id 735530).
6	Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res. 2009 Jun;19(3):267-73.
7	Contribution of protein binding to the pharmacokinetics of the ghrelin receptor agonist TZP-101 in healthy volunteers and adults with symptomatic gastroparesis: two randomized, double-blind studies and a binding profile study. Clin Drug Investig. 2009;29(6):409-18.
8	Orphan GPCR research. Br J Pharmacol. 2008 March; 153(Suppl 1): S339-S346.
9	Hypotensive effects of ghrelin receptor agonists mediated through a novel receptor. Br J Pharmacol. 2014 Mar;171(5):1275-86.
10	Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999 Aug;141(2):180-9.
11	Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clin Pharmacol Ther. 2001 Jul;70(1):91-8.
12	A gift for research. SciBX 7(6); doi:10.1038/scibx.2014.160. Feb. 13 2014